0001828182-22-000056.txt : 20220830 0001828182-22-000056.hdr.sgml : 20220830 20220830161941 ACCESSION NUMBER: 0001828182-22-000056 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220830 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220830 DATE AS OF CHANGE: 20220830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Signify Health, Inc. CENTRAL INDEX KEY: 0001828182 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40028 FILM NUMBER: 221214798 BUSINESS ADDRESS: STREET 1: 800 CONNECTICUT AVENUE CITY: NORWALK STATE: CT ZIP: 06854 BUSINESS PHONE: (203) 541-4600 MAIL ADDRESS: STREET 1: 800 CONNECTICUT AVENUE CITY: NORWALK STATE: CT ZIP: 06854 8-K 1 sgfy-20220830.htm 8-K sgfy-20220830
0001828182false00018281822022-08-302022-08-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 30, 2022
Signify Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
001-40028
85-3481223
(State of Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)
800 Connecticut Avenue
Norwalk, CT
(Address of Principal Executive Offices)
06854
(Zip Code)

Registrant’s telephone number, including area code: (203) 541-4600

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbolName of each exchange on which registered
Class A common stock, par value $0.01 per ShareSGFYNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act




Item 7.01. Regulation FD Disclosure.

On August 30, 2022, the Company issued a press release regarding its collaborative accountable care organizations. A copy of the press release is furnished as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

The foregoing description and the other information provided pursuant to this Item 7.01, including Exhibit 99.1, is “furnished” and shall not be deemed “filed” with the Securities and Exchange Commission (the “SEC”) or incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in any such filings.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.Description
99.1
104Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 104



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


SIGNIFY HEALTH, INC.
Date: August 30, 2022By:/s/ Steve Senneff
Name: Steve Senneff
Title: President and Chief Financial & Administrative Officer




EX-99.1 2 exhibit991083022.htm EX-99.1 Document
Exhibit 99.1
signifyhealthlogo.jpg
PRESS RELEASE


All Signify Health Collaborative ACOs Earn Shared Savings for 2021 Performance

Signify’s provider partners saved more than $138 million in 2021, and all Collaborative ACOs earned 100 percent on their Merit-Based Incentive Payment System scores

Signify achieves record ACO sales for 2023, Collaborative ACOs to reach over 700,000 attributed lives in 2023


DALLAS and NEW YORK – August 30, 2022 – Signify Health, Inc. (NYSE: SGFY), a leading value-based healthcare platform enabled by advanced analytics, technology, and nationwide healthcare networks, today announced that its collaborative accountable care organizations (ACOs) generated more than $138 million in gross savings in 2021. As a result of their strong performance in the Medicare Shared Savings Program, community hospitals and their affiliated physicians earned more than $59 million in shared savings payments. The Company also announced that it has surpassed its target for new ACO bookings in 2023 due to the strong performance and the combined capabilities of Signify Health and Caravan Health.

“These impressive results confirm what we have learned through many years managing outcomes-based payment models – our dedicated population health management leads to quality care while saving money for Medicare,” said Kyle Armbrester, Signify Health CEO. “Our approach and track record has resonated with our clients, allowing us to achieve record ACO sales for 2023 and to surpass 700,000 lives under management in 2023, with nearly 70% of attributed lives expected to be in Enhanced tracks. I’m excited to bring Signify’s in-home capabilities to these new clients in the coming months.”

Signify Health’s success-based pricing model, with no upfront fees, effectively minimizes downside risk and has resulted in all Collaborative ACOs earning MIPS scores of 100% and the maximum positive payment adjustment. MIPS, the Centers for Medicare & Medicaid Services’ value-based measurement program, adjusts Medicare payment rates based on healthcare quality and outcomes.

In 2022, Signify aligned with more than 29,000 providers across more than 40 states, representing more than 500,000 covered lives. Provider organizations participating in Signify’s Collaborative ACOs include health systems, integrated delivery networks, rural and community hospitals, and independent practices. Signify is building on its success with a suite of new services in 2023, including in-home capabilities, Return to Home to support patient care transitions, and analytic enhancements to help providers solve patient problems at the point-of-care.

In March 2022, Signify Health acquired Caravan Health, a leader in guiding ACOs to success with client results that have historically led the nation in earned shared savings and MIPS scores. The acquisition resulted in one of the largest national networks of providers engaged in value-based payment models, with the goal to excel in population health management and value-based payment programs.





Exhibit 99.1
signifyhealthlogo.jpg
About Signify Health

Signify Health is a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare provider networks to create and power value-based payment programs. Our mission is to build trusted relationships to make people healthier. Our solutions support value-based payment programs by aligning financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, coordination, and cost-savings. Through our platform, we coordinate what we believe is a holistic suite of clinical, social, and behavioral services to address an individual’s healthcare needs and prevent adverse events that drive excess cost, all while shifting services towards the home.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release are forward-looking statements. These statements may be preceded by, followed by or include the words “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, achievements or the number of attributed lives. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include: our ability to achieve forecasted new ACO bookings in 2023; our ability to achieve over 700,000 lives under management in 2023; the COVID-19 pandemic and whether the pandemic will continue to subside in 2022; our ability to realize synergies from the acquisition of Caravan Health, Inc.; our dependence on certain key government programs; risks associated with estimating program size, savings rate and patient attribution; our failure to continue to innovate and provide services that are useful to customers and achieve and maintain market acceptance; our limited operating history with certain of our solutions; our failure to compete effectively; the length and unpredictability of our sales cycle; seasonality that may cause fluctuations in our sales, cash flows and results of operations; the information we provide to, or receive from, our health plans and providers could be inaccurate or incomplete; the risk that the cost of services provided will be higher than benchmark prices in our care redesign solutions; failure of our existing customers to continue or renew their contracts with us; failure of service providers to meet their obligations to us; our failure to achieve or maintain profitability; our revenues not growing at the rates they historically have, or at all; our failure to successfully execute on our growth initiatives, business strategies, or operating plans; our failure to successfully launch new products; our failure to effectively adapt to changes in the healthcare industry, including changes in the rules governing Medicare or other federal healthcare programs; our failure to adhere to complex and evolving governmental laws and regulations; our failure to comply with current and future federal and state privacy, security and data protection laws, regulations or standards; adverse findings from inspections, reviews, audits and investigations; inadequate investment in or maintenance of our operating


Exhibit 99.1
signifyhealthlogo.jpg
platform and other information technology and business systems; our ability to develop and/or enhance information technology systems and platforms to meet our changing customer needs; higher than expected investments in our business including, but not limited to, investments in our technology and operating platform, which could reduce our profitability; security breaches or incidents, loss or misuse of data, a failure in or breach of our operational or security systems or other disruptions; disruptions in our disaster recovery systems or management continuity planning; our ability to obtain, maintain, protect and enforce our intellectual property; risks associated with acquiring other businesses including our ability to effectively integrate the operations and technologies of the acquired businesses; and the other risk factors described under “Risk Factors” in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which are available free of charge on the SEC's website at: www.sec.gov.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

# # #

Source: Signify Health

Media contact:
Lynn Shepherd, VP, Corporate and Enterprise Communications
lshepherd@signifyhealth.com


EX-101.SCH 3 sgfy-20220830.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sgfy-20220830_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 sgfy-20220830_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 signifyhealthlogo.jpg begin 644 signifyhealthlogo.jpg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htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Aug. 30, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 30, 2022
Entity Registrant Name Signify Health, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40028
Entity Tax Identification Number 85-3481223
Entity Address, Address Line One 800 Connecticut Avenue
Entity Address, City or Town Norwalk
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06854
City Area Code 203
Local Phone Number 541-4600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, par value $0.01 per Share
Trading Symbol SGFY
Security Exchange Name NYSE
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001828182
Amendment Flag false
XML 8 sgfy-20220830_htm.xml IDEA: XBRL DOCUMENT 0001828182 2022-08-30 2022-08-30 0001828182 false 8-K 2022-08-30 Signify Health, Inc. DE 001-40028 85-3481223 800 Connecticut Avenue Norwalk CT 06854 203 541-4600 false false false false Class A common stock, par value $0.01 per Share SGFY NYSE true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://signifyhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sgfy-20220830.htm exhibit991083022.htm sgfy-20220830.xsd sgfy-20220830_lab.xml sgfy-20220830_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sgfy-20220830.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sgfy-20220830.htm" ] }, "labelLink": { "local": [ "sgfy-20220830_lab.xml" ] }, "presentationLink": { "local": [ "sgfy-20220830_pre.xml" ] }, "schema": { "local": [ "sgfy-20220830.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sgfy", "nsuri": "http://signifyhealth.com/20220830", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgfy-20220830.htm", "contextRef": "i6d233e7bdd3d4b39858721855597dae6_D20220830-20220830", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://signifyhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sgfy-20220830.htm", "contextRef": "i6d233e7bdd3d4b39858721855597dae6_D20220830-20220830", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://signifyhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001828182-22-000056-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001828182-22-000056-xbrl.zip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end